Trials / Completed
CompletedNCT00874185
Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 720 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate satisfaction in people treated with IPDE5 inhibitors over time
Detailed description
12 first patients that are eligible
Conditions
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2009-04-02
- Last updated
- 2021-02-01
Source: ClinicalTrials.gov record NCT00874185. Inclusion in this directory is not an endorsement.